Stoikos Panagiotis, Giannakoulas Angelos, Kouvata Evangelia, Stefani Georgia, Vassilopoulos George, Giannakoulas Nikolaos
Laboratory of Hematology Department, Faculty of Medicine, University of Thessaly, 41110 Larissa, Greece.
Hematology Department, University Hospital of Larissa, 41110 Larissa, Greece.
Oncol Lett. 2025 Jul 17;30(4):448. doi: 10.3892/ol.2025.15194. eCollection 2025 Oct.
Multiple myeloma (MM) is a highly heterogenous disease with diverse outcomes across patients. Stratifying patients is a promising approach to predict their clinical outcomes. However, despite notable progress in stratification systems, there is still a need for further optimization. Combining the existing staging parameters with molecular approaches could offer a better understanding of 'high risk' disease and guide treatment decisions. Bone morphogenetic proteins (BMPs) represent a group of proteins, which are members of the TGF-β superfamily that are now considered to be multifunctional cytokines. BMPs are mostly differentiation factors that are involved in bone metabolism, tissue development and carcinogenesis. In MM, BMP signaling is less well characterized and its association with the pathogenesis of MM is still under investigation. Therefore, the present study aimed to evaluate BMP2 and BMP6 expression and to study the clinical impact of their expression. BMP2 and BMP6 expression was quantified using reverse transcription-quantitative PCR post-RNA extraction from bone marrow mononuclear cells derived from patients with MM and healthy donors. According to the observations in a group of patients with newly diagnosed MM, neither BMP2 nor BMP6 were able to serve as prognostic biomarkers for patients.
多发性骨髓瘤（MM）是一种高度异质性疾病，患者的预后各不相同。对患者进行分层是预测其临床结局的一种有前景的方法。然而，尽管分层系统取得了显著进展，但仍需要进一步优化。将现有的分期参数与分子方法相结合，可以更好地理解“高危”疾病并指导治疗决策。骨形态发生蛋白（BMPs）是一组蛋白质，属于转化生长因子-β（TGF-β）超家族成员，现在被认为是多功能细胞因子。BMPs大多是参与骨代谢、组织发育和致癌作用的分化因子。在MM中，BMP信号传导的特征尚不明确，其与MM发病机制的关联仍在研究中。因此，本研究旨在评估BMP2和BMP6的表达，并研究其表达的临床影响。从MM患者和健康供体的骨髓单个核细胞中提取RNA后，使用逆转录定量PCR对BMP2和BMP6的表达进行定量。根据一组新诊断MM患者的观察结果，BMP2和BMP6均不能作为患者的预后生物标志物。
